BRCA1 & BRCA2 MUTATION DRUG PROFILING PANEL
This assay detects most of the mutations and insertions/deletions in the BRCA gene which is linked to breast/ovarian cancer. Using the Oncomine Knowledge base, this assay predicts the response of drugs such as PARP inhibitors and helps to tailor the therapy. PARP inhibition results in selective killing of cancer cells which have lost BRCA1 or BRCA2 function.
Parameter(s) covered : 1
Report Frequency: Sample Mon by 9 am; Report 15 Working days
Special Instruction: Duly filled BRCA 1 & 2 informed consent form for genetic testing (Form 24) is mandatory.
Price : ₹ 23800.00
Parameters
- BRCA1 & BRCA2 MUTATION DRUG PROFILING PANEL